MilliporeSigma Webinars
-
AAV Gene Therapy: Orthogonal Methods To Understand And Define CQAs
10/13/2021
As with all biopharmaceuticals, it is important to identify and monitor the critical quality attributes (CQAs) of these products to ensure their safety and efficacy. Our experts present a range of orthogonal methods to understand and define the CQAs of AAV products.
-
Better Bioprocessing Efficiency Through Centralized Orchestration
10/7/2021
Learn how orchestration software improves bioprocessing efficiency through the centralized configuration and management of connected unit operations for process and workflow automation across the plant floor.
-
Achieving High Yields In Scalable Xeno-Free Culture Formats With Mesenchymal Stem Cell Medium
7/27/2021
In this webinar, we will explore the current landscape and future trends of cell culture media for adult mesenchymal stem cells and discuss the options to derive MSC’s from bone marrow in xeno-free conditions from static to microcarrier-based suspension culture platforms. Finally, we will demonstrate the Stemline® XF MSC Media we’ve developed to reduce scalability roadblocks while maintaining robust performance.
-
Which Ingredient Are You Missing In Your Gene Therapy Success Recipe?
3/25/2021
In this podcast, Ratish Krishnan, Associate Director for Cell & Gene Therapy talks about the tremendous promise gene therapies have for changing the healthcare paradigm and solutions to some of the biggest challenges in gene therapy manufacturing.
-
Developing A Scalable Upstream Bioreactor Process For Lentiviral Vector Production In Suspension
3/8/2021
Gene therapies hold the promise to change lives. As your path to patients accelerates, how can you assure the robust process design, intensification and scalability that meets your evolving manufacturing needs? And what benefits can a templated process bring to your commercial success? Learn the answers to these questions and more in this webinar.
-
Biosafety In Gene Therapy: Applying The Latest Regulatory Guidance For RCL Testing
2/23/2021
The use of lentivirus vectors to produce groundbreaking gene therapies is on the rise. Ensuring the biosafety and quality of these vectors is achieved through a multi-tiered testing approach. For lentivirus-based therapies, generation of replication competent particles is a potential risk. While improvements in design and manufacturing have decreased the probability of producing replication competent viruses, regulatory agencies provide guidelines to test for their presence at multiple stages in production.
-
Addressing The Challenge Of Scalability In Viral Vectors
10/18/2020
Early viral vector process development for cell and gene therapies is critical to assure a production strategy that supports commercial needs. In this webinar, you will learn the importance of planning for scalability and manufacturability from the earliest stages of process development and how a scalable templated process can reduce time needed to move from product development to commercialization.
-
Navigating The Road To Gene Therapy Commercialization
8/27/2020
With increases in development and investments in the gene therapy field, companies will increasingly be looking at manufacturing and commercialization of their therapies. Road to commercialization goes through a series of process validation phases. In this webinar, we take a closer look at the road to commercialization and focus on addressing primary questions.
-
Downstream Process Intensification For Virus Purification
8/21/2020
With the rise of gene therapy as a promising treatment modality, the industry is facing increasing pressure to decrease overall manufacturing costs, shorten product development timelines and increase production. This webinar focuses on intensified downstream process using high-productivity, single-use chromatography membrane adsorbers.
-
Process Development for Cell Therapy and Viral Gene Therapy
10/29/2019
In this webinar, we discuss our strategies for developing lentivirus and adeno associated virus (AAV) and the impact these early decisions can have on commercial readiness.